NEW DELHI: Gilead Sciences Inc late Monday said results from its phase-three clinical trial among hospitalised patients with mild covid-19 pneumonia showed that a five-day treatment course of remdesivir can lead to significant clinical improvement.
Patients in the five-day remdesivir treatment group were 65% more likely to have clinical improvement on day 11, compared with those in standard care group, the company said.
The Drugs Controller General of India (DCGI), VG Somani, has also approved the drug for a five-day treatment, a source at the apex Indian drug regulator told Mint, requesting anonymity.
However, the approval has yet not been made public. In India, Gilead has given voluntary licenseto produce remdesivir to Cipla Ltd,